Novel Radiotracers in PET Imaging

This article reviews emerging PET radiopharmaceuticals in late preclinical and early clinical development. The discussed tracers have broad applications for disease staging, theranostic patient selection, and treatment monitoring. For oncology, tracers targeting fibroblast activation protein, prostate-specific membrane antigen, delta-like ligand 3, trophoblast cell-surface antigen 2, claudin 18.2, and amino-acid transporters are highlighted alongside immune-targeted tracers imaging cluster of differentiation proteins, the programmed death-1 receptor and ligand, granzyme B, and macrophages. In neurology, tracers targeting amyloid-beta, tau, translocator protein, and synaptic vesicle protein 2A are discussed. Highlighted cardiology tracers focus on imaging of myocardial perfusion, amyloidosis, and vascular inflammation.